Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two‐Stage Pharmacokinetic Analysis

The disposition of amiodarone, an antiarrhythmic agent was evaluated after a single intravenous infusion (5 mg/kg over 15 minutes) in patients of various ages and with various degrees of renal function and left ventricular function. The plasma concentration—time data were obtained from three clinical studies with similar protocols. The data were analyzed by nonlinear mixed‐effects modeling (NONMEM) to estimate the population pharmacokinetic parameters of amiodarone and to determine the significant demographic covariates affecting these parameters. The pharmacokinetic parameters of amiodarone (weight‐corrected) also were calculated using two‐stage analysis and were compared with the results obtained from the mixed‐effects analysis. The population plasma concentration—time profile of amiodarone was best described by a four‐compartment model. Demographic covariates (i.e., creatinine clearance and ejection fraction) did not improve the final pharmacostatistical model significantly. The results from the two‐stage analysis showed no significant relationship between amiodarone pharmacokinetic parameters and age, gender, renal function, or ejection fraction. The results from one study, however, demonstrated that advanced age (≥65 years) resulted in reduced amiodarone clearance coupled with a prolonged elimination half‐life. No such correlation was detected with NONMEM analysis, which may be partly attributable to the small number of elderly patients. Overall, the results from NONMEM analysis validated the results obtained from the two‐stage analysis.

[1]  Sloskey Ge Amiodarone: a unique antiarrhythmic agent. , 1983 .

[2]  H. Greene The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. , 1989, Progress in cardiovascular diseases.

[3]  M. Rubenfire,et al.  Hemodynamic Effects of Antiarrhythmic Drugs , 1991, Journal of clinical pharmacology.

[4]  M. Gibaldi,et al.  Pharmacokinetics, Second Edition , 1982 .

[5]  J. Kluger,et al.  Pharmacokinetics of Intravenous Amiodarone in Patients with Impaired Left Ventricular Function , 1996, Journal of clinical pharmacology.

[6]  M. Anastasiou-Nana,et al.  Pharmacokinetics of amiodarone after intravenous and oral administration. , 1982, International journal of clinical pharmacology, therapy, and toxicology.

[7]  M. Chow,et al.  Disposition of Intravenous Amiodarone in Subjects with Normal and Impaired Renal Function , 1996, Journal of clinical pharmacology.

[8]  W. Mckenna,et al.  Renal elimination of amiodarone and its desethyl metabolite. , 1983, Postgraduate medical journal.

[9]  G R Wilkinson,et al.  Clearance approaches in pharmacology. , 1987, Pharmacological reviews.

[10]  D. Roden Pharmacokinetics of amiodarone: implications for drug therapy. , 1993, The American journal of cardiology.

[11]  F. Morady,et al.  Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. , 1983, American heart journal.

[12]  L. Horowitz,et al.  Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. , 1989, Progress in cardiovascular diseases.

[13]  W. Remme,et al.  Acute hemodynamic and antiischemic effects of intravenous amiodarone. , 1985, The American journal of cardiology.

[14]  D. Holt,et al.  High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400-mg dose. , 1982, Journal of chromatography.

[15]  G. Sloskey Amiodarone: a unique antiarrhythmic agent. , 1983, Clinical pharmacy.

[16]  G. Nau,et al.  Clinical efficacy of amiodarone as an antiarrhythmic agent. , 1976, The American journal of cardiology.

[17]  A. Morley,et al.  Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. , 1985, Circulation.

[18]  M. E. Veronese,et al.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. , 1988, British journal of clinical pharmacology.

[19]  R. Grolleau,et al.  A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. , 1988, European heart journal.

[20]  J. Korth-Bradley,et al.  Population Pharmacokinetics of Intravenous Amiodarone in Patients with Refractory Ventricular Tachycardia/Fibrillation , 1996, Journal of clinical pharmacology.

[21]  M. D. Freedman,et al.  Pharmacology and Pharmacokinetics of Amiodarone , 1991, Journal of clinical pharmacology.

[22]  P. Somani Basic and Clinical Pharmacology of Amiodarone: Relationship of Antiarrhythmic Effects, Dose and Drug Concentrations to Intracellular Inclusion Bodies , 1989, Journal of clinical pharmacology.

[23]  J. Barthélémy,et al.  Acute Hemodynamic Effects of Intravenous Amiodarone in Patients with Coronary Artery Disease , 1985, Journal of cardiovascular pharmacology.

[24]  E. V. Vaughan Williams Classifying antiarrhythmic actions: by facts or speculation. , 1992, Journal of clinical pharmacology.

[25]  K. Nademanee,et al.  The historical development, cellular electrophysiology and pharmacology of amiodarone. , 1989, Progress in cardiovascular diseases.

[26]  E. Prystowsky,et al.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. , 1981, The New England journal of medicine.